Risk adjusted net present value: What is the current valuation of Novo Nordisk’s (Insulin icodec + Semaglutide)?

(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III program in Type 2 Diabetes.

In-hospital delirium linked to long-term cognitive impairment in COVID-19 patients over 60

The association of in-hospital delirium with functional disability and cognitive impairment.

July 4, 2024

AI revolutionizes malaria diagnosis with 97.57% accuracy using EfficientNet

AI tool that uses deep learning to examine red blood cell images in blood smears for the timely detection of malaria.

June 12, 2024

Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.